Aligos Therapeutics, Inc. (ALGS)
Stock Price:
$14.76 USD
-0.09 (-0.61%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
After-hours: $14.60 -0.16 (-1.08%) Oct 19, 7:33 PM
Key Info
| Market Cap |
498.86M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-73.06M |
| Shares Out |
36.89M |
| EPS (ttm) |
-1.98 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 19, 2020 |
| Last Price |
$14.76 |
| Previous Close |
$14.85 |
| Change ($) |
-0.09 |
| Change (%) |
-0.61% |
| Day's Open |
14.74 |
| Day's Range |
14.00 - 15.00 |
| Day's Volume |
342,381 |
| 52-Week Range |
13.63 - 17.50 |
More Stats
| Market Cap |
498.86M |
| Enterprise Value |
423.89M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
36.89M |
| Float |
14.98M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-1.98 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
n/a |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
-73.06M |
| Free Cash Flow |
n/a |
| Net Cash |
74.96M |
| Net Cash / Share |
2.22 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -54.04 | -13.66 |
| Net Income | -52.26 | -13.93 |
| Shares Outstanding | 18.83 | 11.11 |
| Earnings Per Share | -2.78 | -1.25 |
| Operating Cash Flow | -46.77 | -6.05 |
| Capital Expenditures | -2.79 | -2.52 |
| Free Cash Flow | -49.55 | -8.57 |
| Cash & Equivalents | 118 | 91.36 |
| Total Debt | 14.33 | 13.86 |
| Net Cash / Debt | 104 | 77.50 |
| Assets | 147 | 108 |
| Liabilities | 29.33 | 20.96 |
| Book Value | -64.89 | -13.75 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aligos Therapeutics, Inc. |
| Country |
United States |
| Employees |
67 |
| CEO |
Lawrence M. Blatt |
Stock Information
| Ticker Symbol |
ALGS |
| Stock Exchange |
NASDAQ |
| Sector |
Health Technology |
| Industry |
Pharmaceuticals: Major |
| Unique Identifier |
NASDAQ: ALGS |
| IPO Date |
October 16, 2020 |
Description
Aligos Therapeutics develops targeted, curative therapies for hepatologic diseases and viral infections. It engages in building a pipeline of drug candidates which targets multiple clinically validated mechanisms of action and are designed to achieve functional cure for CHB and become transformative treatment options for COVID-19 and NASH. The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.